WUXI BIO(02269),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02269 WUXI BIO

Closed 02-05 16:08:28

37.520

+0.960

+2.63%

High37.620	Low36.280	Vol28.13M
Open36.280	D1 Closing36.560	Amplitude3.67%
Mkt Cap155.26B	Tradable Cap155.26B	Total Shares4.14B
T/O1.04B	T/O Rate0.68%	Tradable Shares4.14B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02269","market":"HK","secType":"STK","nameCN":"WUXI BIO","latestPrice":37.52,"timestamp":1770278908004,"preClose":36.56,"halted":0,"volume":28128398,"delay":0,"changeRate":0.026258205689277923,"floatShares":4138000000,"shares":4138000000,"eps":0.8833075628662052,"marketStatus":"Closed","change":0.96,"latestTime":"02-05 16:08:28","open":36.28,"high":37.62,"low":36.28,"amount":1044337580,"amplitude":0.036652,"askPrice":37.52,"askSize":443500,"bidPrice":37.5,"bidSize":81500,"shortable":3,"etf":0,"ttmEps":1.1127424261964656,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770341400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1497283200000,"exchange":"SEHK","adjPreClose":36.56,"openAndCloseTimeList":[[1770255000000,1770264000000],[1770267600000,1770278400000]],"volumeRatio":0.848555,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"WXB.HK","impliedVol":0.4695,"impliedVolPercentile":0.1526},"requestUrl":"/m/hq/s/02269","defaultTab":"news","newsList":[{"id":"2609099324","title":"Wuxi Biologics (Cayman) Stock Advances 2.6% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2609099324","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609099324?lang=en_us&edition=fundamental","pubTime":"2026-02-05 16:31","pubTimestamp":1770280260,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rose 2.6% to 37.52 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.1% to 26885.24.Wuxi Biologics  Inc. closed 12% below its 52-week high of HK$42.60, which the company achieved Oct. 3.Trading volume totaled 28.1 million shares, compared to the 50-day average of 35.3 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","LU0039217434.USD","LU0326950275.SGD","LU0327786744.USD","LU0348825331.USD","LU0052750758.USD","SG9999002562.SGD","BK1141","LU0181495838.USD","BK1610","LU0516422440.USD","LU0417516738.SGD","LU0516422366.SGD","LU1242518931.SGD","IE00B0JY6N72.USD","LU0588546209.SGD","LU0823426480.USD","LU0516422952.EUR","LU0572944931.SGD","LU0307460666.USD","LU0359201612.USD","91347","LU0359202008.SGD","LU3063872942.SGD","LU0456827905.SGD","LU0320764599.SGD","LU1720050803.USD","LU0856984785.SGD","LU0819121731.USD","LU2039709279.SGD","LU1688375341.USD","BK1521","LU0979878070.USD","LU0456846285.SGD","LU0516423174.USD","LU0051755006.USD","BK1589","BK1576","LU0516423091.SGD","LU0140636845.USD","LU0348735423.USD","LU1794554557.SGD","LU0043850808.USD","LU0823426308.USD","LU1880383366.USD","LU0708995583.HKD","LU1242518857.USD","LU0417516902.SGD","SG9999002463.SGD"],"gpt_icon":0},{"id":"2608360387","title":"Wuxi XDC Cayman Inc. verschiebt Versand der Angebotsunterlagen","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360387","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608360387?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:10","pubTimestamp":1770214226,"startTime":"0","endTime":"0","summary":"Wuxi XDC Cayman Inc. hat gemeinsam mit BioDlink International Company Limited ein freiwilliges Barangebot für alle ausstehenden Aktien des Unternehmens unterbreitet, mit Ausnahme der bereits vom Bieter und dessen verbundenen Parteien gehaltenen oder zum Erwerb vereinbarten Aktien. Zudem sollen alle ausstehenden Aktienoptionen annulliert werden. Die Verffentlichung der entsprechenden Angebotsunterlagen verzgert sich gegenüber der ursprünglichen Planung.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi XDC Cayman Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 04, 2026, and is solely responsible for the information cont","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL5G2sH3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0043850808.USD","LU0516423091.SGD","LU0588546209.SGD","LU0039217434.USD","LU2488822045.USD","LU0051755006.USD","LU1242518931.SGD","LU3063872942.SGD","LU0516422440.USD","LU0307460666.USD","LU0140636845.USD","LU0348825331.USD","LU0516422952.EUR","LU0823426308.USD","LU0823426480.USD","LU0348735423.USD","LU0320764599.SGD","LU0819121731.USD","LU1688375341.USD","LU0456846285.SGD","LU1242518857.USD","LU0417516738.SGD","LU0327786744.USD","LU0516422366.SGD","02268","SG9999002463.SGD","LU0456827905.SGD","SG9999014674.SGD","LU0856984785.SGD","LU0979878070.USD","BK1589","LU1880383366.USD","LU1794554557.SGD","IE00B0JY6N72.USD","LU1720050803.USD","BK1610","LU0516423174.USD","LU0052750758.USD","BK1576","LU2039709279.SGD","BK1141","LU0326950275.SGD","LU0417516902.SGD","BK1521","SG9999002562.SGD","02269","LU0181495838.USD","LU0708995583.HKD","LU0359201612.USD","LU0572944931.SGD"],"gpt_icon":0},{"id":"2608673033","title":"TOT BIOPHARM Delays Dispatch of Composite Offer Document","url":"https://stock-news.laohu8.com/highlight/detail?id=2608673033","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608673033?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:53","pubTimestamp":1770213189,"startTime":"0","endTime":"0","summary":"WuXi XDC Cayman Inc. and BioDlink International Company Limited have provided an update regarding the proposed acquisition of all issued shares of TOT BIOPHARM International Co. Ltd., excluding those already owned or agreed to be acquired by the offeror and its concert parties. The companies announced a delay in the despatch of the composite document relating to the transaction. Further details, including the recommendations of the Independent Board Committee and the advice of the Independent Financial Adviser, will be provided in the forthcoming composite document.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOT BIOPHARM International Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Infor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL28BJyT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456846285.SGD","LU0348825331.USD","LU0417516738.SGD","02268","LU0359201612.USD","LU1720050803.USD","BK1610","LU0140636845.USD","LU0051755006.USD","LU0588546209.SGD","BK1161","LU0823426480.USD","LU0039217434.USD","LU0516423091.SGD","LU1794554557.SGD","LU0856984785.SGD","LU2488822045.USD","01875","BK1589","BK1141","LU0417516902.SGD","LU0708995583.HKD","LU0307460666.USD","LU0348735423.USD","LU0516422952.EUR","02269","LU0823426308.USD","LU0572944931.SGD","LU0819121731.USD","LU0327786744.USD","SG9999002562.SGD","LU1880383366.USD","LU0052750758.USD","LU1688375341.USD","LU2039709279.SGD","SG9999014674.SGD","LU0326950275.SGD","BK1574","LU1242518931.SGD","LU0359202008.SGD","BK1521","LU1242518857.USD","LU3063872942.SGD","LU0979878070.USD","LU0043850808.USD","LU0516422366.SGD","BK1576","LU0320764599.SGD","LU0181495838.USD","LU0516423174.USD"],"gpt_icon":0},{"id":"2608368531","title":"Assessing WuXi Biologics (SEHK:2269) Valuation After New Autoimmune And Biologics Collaboration Wins","url":"https://stock-news.laohu8.com/highlight/detail?id=2608368531","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608368531?lang=en_us&edition=fundamental","pubTime":"2026-02-04 16:27","pubTimestamp":1770193646,"startTime":"0","endTime":"0","summary":"WuXi Biologics (Cayman) (SEHK:2269) has drawn fresh attention after entering into a license and research service agreement with Vertex Pharmaceuticals for trispecific T cell engagers targeting B cell mediated autoimmune diseases.\nSee our latest analysis for WuXi Biologics (Cayman).\nThose fresh collaborations with Vertex, Sinorda and HanchorBio arrive as WuXi Biologics’ share price sits at HK$36.98, with a 1 month share price return of 13.64% and a 1 year total shareholder return of 87.91%...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/assessing-wuxi-biologics-sehk2269-valuation-after-new-autoim","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/assessing-wuxi-biologics-sehk2269-valuation-after-new-autoim","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0307460666.USD","LU0359201612.USD","LU0572944931.SGD","LU0181495838.USD","LU0516422952.EUR","LU0979878070.USD","LU0327786744.USD","LU0588546209.SGD","LU0516422440.USD","LU0456846285.SGD","LU3063872942.SGD","LU0051755006.USD","LU0823426480.USD","LU1242518931.SGD","LU1242518857.USD","LU0140636845.USD","02269","SG9999002562.SGD","LU0359202008.SGD","LU0348825331.USD","LU0417516902.SGD","LU0819121731.USD","LU0708995583.HKD","LU0320764599.SGD","BK1610","LU1794554557.SGD","LU0039217434.USD","LU2039709279.SGD","BK1576","LU0417516738.SGD","LU1688375341.USD","LU0043850808.USD","LU0823426308.USD","LU0516422366.SGD","BK1521","BK1141","91347","LU0326950275.SGD","BK1589","IE00B0JY6N72.USD","LU0348735423.USD","LU1880383366.USD","SG9999002463.SGD","LU0516423174.USD","LU0516423091.SGD","LU1720050803.USD","LU0856984785.SGD","LU0052750758.USD","LU0456827905.SGD"],"gpt_icon":0},{"id":"2608848142","title":"WuXi Biologics Signs License and Research Service Agreement with Vertex Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2608848142","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608848142?lang=en_us&edition=fundamental","pubTime":"2026-02-03 11:09","pubTimestamp":1770088141,"startTime":"0","endTime":"0","summary":"WuXi Biologics  Inc. announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated for the development of an innovative trispecific T-cell Engager for the treatment of B-cell mediated autoimmune diseases. This agreement provides Vertex with access to WuXi Biologics' research and development capabilities to support the advancement of this molecule.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics  Inc. published the original content used to generate this news brief via CNW  on February 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL3pjlfK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0140636845.USD","LU1688375341.USD","LU1720050803.USD","BK1576","LU0417516738.SGD","LU1242518931.SGD","SG9999002562.SGD","BK1610","LU0417516902.SGD","LU0359202008.SGD","02269","LU0856984785.SGD","LU0326950275.SGD","LU0516422366.SGD","LU1794554557.SGD","LU0708995583.HKD","LU2039709279.SGD","LU1242518857.USD","LU0572944931.SGD","BK1141","LU3063872942.SGD","LU0516423174.USD","SG9999002463.SGD","BK1589","IE00B0JY6N72.USD","LU0516423091.SGD","LU0043850808.USD","LU0823426480.USD","BK1521","LU0456827905.SGD","LU0039217434.USD","LU0052750758.USD","LU0819121731.USD","LU0307460666.USD","LU0320764599.SGD","LU0327786744.USD","LU1880383366.USD","LU0348825331.USD","LU0979878070.USD","LU0051755006.USD","LU0348735423.USD","LU0516422440.USD","LU0456846285.SGD","LU0516422952.EUR","LU0588546209.SGD","LU0181495838.USD","LU0823426308.USD","LU0359201612.USD"],"gpt_icon":0},{"id":"2608684814","title":"WuXi Biologics schließt Lizenz- und Forschungsdienstleistungsvertrag mit Vertex Pharmaceuticals für T-Zell-Engager ab","url":"https://stock-news.laohu8.com/highlight/detail?id=2608684814","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608684814?lang=en_us&edition=fundamental","pubTime":"2026-02-03 11:09","pubTimestamp":1770088141,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics  Inc. published the original content used to generate this news brief via CNW  on February 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL6yXjkH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0140636845.USD","LU1674673428.USD","LU1720050803.USD","BK1576","LU0417516738.SGD","IE00BZ9MQY76.HKD","SG9999002562.SGD","LU1778281490.HKD","BK4139","IE00BJJMRZ35.SGD","LU0417516902.SGD","LU0359202008.SGD","02269","SG9999001176.USD","LU0823416689.USD","LU0061475181.USD","LU2236285917.USD","LU1794554557.SGD","LU2362541513.USD","IE0002141913.USD","LU0708995583.HKD","LU2039709279.SGD","SG9999001176.SGD","LU1242518857.USD","LU0572944931.SGD","IE0002270589.USD","BK1141","LU3063872942.SGD","IE00B0JY6N72.USD","LU0516423091.SGD","LU2324357040.USD","LU0043850808.USD","LU0456827905.SGD","LU0039217434.USD","LU0052750758.USD","LU0819121731.USD","LU0320764599.SGD","LU0327786744.USD","LU1069344957.HKD","LU1880383366.USD","LU0979878070.USD","BK4533","LU0058720904.USD","LU0051755006.USD","LU0432979614.USD","LU2237438978.USD","LU1242518931.SGD","LU0359201612.USD","BK4588","VRTX"],"gpt_icon":0},{"id":"2608848117","title":"WuXi Biologics and Vertex Sign License and Research Service Agreement for T-Cell Engager","url":"https://stock-news.laohu8.com/highlight/detail?id=2608848117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608848117?lang=en_us&edition=fundamental","pubTime":"2026-02-03 11:08","pubTimestamp":1770088116,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUABDTK9K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0456846285.SGD","LU0823426308.USD","LU0588546209.SGD","LU3063872942.SGD","LU1242518857.USD","LU0348825331.USD","LU2039709279.SGD","LU0417516738.SGD","IE00B0JY6N72.USD","LU0140636845.USD","LU0708995583.HKD","LU0043850808.USD","LU0320764599.SGD","LU0052750758.USD","LU0051755006.USD","LU0348735423.USD","LU0572944931.SGD","LU0516422440.USD","BK1141","LU0456827905.SGD","SG9999002562.SGD","LU0417516902.SGD","LU0516422952.EUR","LU0516422366.SGD","LU0516423174.USD","LU0181495838.USD","LU1794554557.SGD","LU0359202008.SGD","LU0326950275.SGD","LU0979878070.USD","LU1720050803.USD","LU1242518931.SGD","LU0823426480.USD","BK1589","LU0327786744.USD","BK1576","BK1610","LU0819121731.USD","LU1688375341.USD","SG9999002463.SGD","LU0307460666.USD","LU1880383366.USD","02269","LU0516423091.SGD","LU0856984785.SGD","BK1521","LU0359201612.USD","LU0039217434.USD"],"gpt_icon":0},{"id":"2608859923","title":"Wuxi Biologics (Cayman) Stock Slides 3.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2608859923","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608859923?lang=en_us&edition=fundamental","pubTime":"2026-02-02 16:32","pubTimestamp":1770021120,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. slipped 3.1% to 35.86 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 2.2% to 26775.57.This was the stock's third consecutive day of losses.Wuxi Biologics  Inc. closed 16% below its 52-week high of HK$42.60, which the company reached Oct. 3.Trading volume totaled 43.7 million shares, compared to the 50-day average of 35.3 million shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0819121731.USD","LU0856984785.SGD","LU0572944931.SGD","LU1688375341.USD","LU0307460666.USD","LU1242518857.USD","LU0043850808.USD","LU0516422952.EUR","BK1576","LU0359202008.SGD","91347","LU0140636845.USD","LU0708995583.HKD","LU3063872942.SGD","LU0417516902.SGD","LU0516422366.SGD","BK1589","BK1610","LU0181495838.USD","LU1242518931.SGD","LU0051755006.USD","LU0359201612.USD","LU0516423174.USD","LU0039217434.USD","LU0052750758.USD","LU0456827905.SGD","LU0327786744.USD","LU0979878070.USD","LU1720050803.USD","LU0516422440.USD","LU0516423091.SGD","LU0823426308.USD","SG9999002463.SGD","02269","LU0417516738.SGD","LU1794554557.SGD","LU0320764599.SGD","SG9999002562.SGD","BK1521","LU0326950275.SGD","LU0823426480.USD","IE00B0JY6N72.USD","LU1880383366.USD","LU0348735423.USD","BK1141","LU0456846285.SGD","LU0588546209.SGD","LU2039709279.SGD","LU0348825331.USD"],"gpt_icon":0},{"id":"2607097756","title":"Wuxi Biologics (Cayman) Stock Sheds 2.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2607097756","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607097756?lang=en_us&edition=fundamental","pubTime":"2026-01-30 16:33","pubTimestamp":1769761980,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. shed 2.4% to 37.00 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 2.1% to 27387.11.This was the stock's second consecutive day of losses.Wuxi Biologics  Inc. closed 13% short of its 52-week high of HK$42.60, which the company achieved Oct. 3.Trading volume totaled 25.4 million shares, compared to the 50-day average of 35.5 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0051755006.USD","LU0516423091.SGD","LU0052750758.USD","LU1242518931.SGD","LU0181495838.USD","BK1589","LU0348735423.USD","LU0039217434.USD","LU0348825331.USD","LU0823426308.USD","SG9999002463.SGD","LU0708995583.HKD","BK1141","LU0516422440.USD","LU0359201612.USD","02269","BK1521","LU0572944931.SGD","LU0456846285.SGD","LU0456827905.SGD","LU0417516738.SGD","LU0417516902.SGD","LU1688375341.USD","LU0140636845.USD","LU0359202008.SGD","LU0516422952.EUR","LU0516423174.USD","LU0856984785.SGD","LU0043850808.USD","LU0320764599.SGD","LU0819121731.USD","LU1720050803.USD","LU0327786744.USD","LU1880383366.USD","LU0307460666.USD","BK1610","LU0516422366.SGD","LU0979878070.USD","LU0326950275.SGD","LU0588546209.SGD","BK1576","SG9999002562.SGD","IE00B0JY6N72.USD","LU0823426480.USD","LU3063872942.SGD","LU2039709279.SGD","LU1242518857.USD","91347","LU1794554557.SGD"],"gpt_icon":0},{"id":"2607677556","title":"WuXi Biologics and Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2607677556","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607677556?lang=en_us&edition=fundamental","pubTime":"2026-01-29 10:40","pubTimestamp":1769654433,"startTime":"0","endTime":"0","summary":"WuXi Biologics  Inc. has entered into a strategic collaboration with Sinorda Biomedicine to accelerate the development and manufacturing of SND006, a novel bispecific antibody targeting inflammatory bowel disease and other autoimmune diseases. Under the partnership, Sinorda Biomedicine will utilize WuXi Biologics' expertise and manufacturing capabilities to advance SND006 through preclinical pharmacology studies and clinical supply, expediting the Investigational New Drug  application process in both China and the United States. The collaboration aims to address unmet medical needs in autoimmune diseases and may expand to include additional projects from Sinorda Biomedicine's pipeline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wux","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL51NwRv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","LU1242518857.USD","LU0043850808.USD","LU0516422366.SGD","LU1242518931.SGD","LU0708995583.HKD","BK1610","LU0307460666.USD","LU0051755006.USD","BK1589","LU1794554557.SGD","LU0327786744.USD","LU0417516902.SGD","LU1720050803.USD","LU0140636845.USD","LU0823426308.USD","IE00B0JY6N72.USD","LU3063872942.SGD","LU0979878070.USD","SG9999002562.SGD","LU0516422952.EUR","LU0456827905.SGD","LU0516423174.USD","LU0326950275.SGD","LU0588546209.SGD","LU0039217434.USD","LU0181495838.USD","LU1880383366.USD","SG9999002463.SGD","LU0052750758.USD","BK1576","LU0819121731.USD","LU0359202008.SGD","LU0359201612.USD","LU0456846285.SGD","LU1688375341.USD","LU0823426480.USD","BK1141","LU0516422440.USD","LU0516423091.SGD","BK1521","02269","LU0856984785.SGD","LU0572944931.SGD","LU2039709279.SGD","LU0417516738.SGD","LU0348825331.USD","LU0320764599.SGD"],"gpt_icon":0},{"id":"2607755687","title":"WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2607755687","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607755687?lang=en_us&edition=fundamental","pubTime":"2026-01-29 10:40","pubTimestamp":1769654417,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nTUA6FJ75P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0417516738.SGD","LU0823426308.USD","LU0572944931.SGD","02269","LU0516422952.EUR","LU0051755006.USD","LU0052750758.USD","BK1610","LU0588546209.SGD","SG9999002463.SGD","LU0320764599.SGD","LU0359201612.USD","LU0819121731.USD","BK1521","LU0307460666.USD","LU0516423174.USD","LU0516422366.SGD","BK1576","IE00B0JY6N72.USD","LU0348825331.USD","LU0856984785.SGD","LU0456827905.SGD","LU0140636845.USD","LU1242518857.USD","LU1720050803.USD","LU1688375341.USD","LU0359202008.SGD","LU1794554557.SGD","LU0181495838.USD","LU3063872942.SGD","BK1589","LU0417516902.SGD","LU0979878070.USD","LU2039709279.SGD","LU0708995583.HKD","LU0326950275.SGD","LU1880383366.USD","LU0516422440.USD","LU0823426480.USD","LU0039217434.USD","LU0043850808.USD","LU0327786744.USD","LU1242518931.SGD","BK1141","LU0456846285.SGD","LU0348735423.USD","SG9999002562.SGD","LU0516423091.SGD"],"gpt_icon":0},{"id":"2606570218","title":"Wuxi Biologics (Cayman) Stock Slides 2.8% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2606570218","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606570218?lang=en_us&edition=fundamental","pubTime":"2026-01-26 16:32","pubTimestamp":1769416320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. shed 2.8% to 38.22 Hong Kong dollars on what proved to be an all-around favorable trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.1% to 26765.52.The stock's fall snapped a three-day winning streak.Wuxi Biologics  Inc. closed 10% short of its 52-week high of HK$42.60, which the company reached Oct. 3.Trading volume totaled 27.6 million shares, compared to the 50-day average of 36.0 million shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","LU1720050803.USD","LU2039709279.SGD","LU0326950275.SGD","LU0708995583.HKD","LU0140636845.USD","BK1589","LU0516422440.USD","LU0456846285.SGD","LU0359201612.USD","LU0456827905.SGD","LU0320764599.SGD","LU0516422952.EUR","LU0819121731.USD","LU0181495838.USD","LU0359202008.SGD","LU0348825331.USD","LU1242518931.SGD","LU0823426480.USD","LU1794554557.SGD","BK1141","BK1521","BK1610","LU0052750758.USD","02269","LU3063872942.SGD","LU1688375341.USD","IE00B0JY6N72.USD","LU0051755006.USD","LU1242518857.USD","LU0588546209.SGD","LU0572944931.SGD","LU0823426308.USD","LU0417516902.SGD","LU0417516738.SGD","LU0979878070.USD","SG9999002562.SGD","LU0043850808.USD","LU0856984785.SGD","LU0516423091.SGD","LU0348735423.USD","LU1880383366.USD","BK1576","LU0516422366.SGD","LU0039217434.USD","SG9999002463.SGD","LU0327786744.USD","91347","LU0516423174.USD"],"gpt_icon":0},{"id":"2605547327","title":"BRIEF-Morgan Stanley’S Long Position In WuXi Biologics (Cayman) Decreases To 2.11% On Jan 20 From 5.58%, HKEX Shows","url":"https://stock-news.laohu8.com/highlight/detail?id=2605547327","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605547327?lang=en_us&edition=fundamental","pubTime":"2026-01-23 17:33","pubTimestamp":1769160825,"startTime":"0","endTime":"0","summary":"BRIEF-Morgan Stanley’S Long Position In WuXi Biologics  Decreases To 2.11% On Jan 20 From 5.58%, HKEX ShowsJan 23  - HKEX:MORGAN STANLEY’S LONG POSITION IN WUXI BIOLOGICS  DECREASES TO 2.11% ON JAN 20 FROM 5.58%Further company coverage: 2269.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nFWN3YO096:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","LU0516423174.USD","BK1589","LU0140636845.USD","LU0516422366.SGD","LU0359202008.SGD","IE00B0JY6N72.USD","LU1720050803.USD","LU1242518931.SGD","LU1880383366.USD","LU0051755006.USD","LU0327786744.USD","LU0516422952.EUR","LU3063872942.SGD","LU0823426308.USD","LU0456846285.SGD","LU0052750758.USD","LU1688375341.USD","LU0417516902.SGD","LU0708995583.HKD","LU0326950275.SGD","BK1141","LU0856984785.SGD","LU0572944931.SGD","LU0417516738.SGD","SG9999002463.SGD","LU1794554557.SGD","LU0043850808.USD","LU0516422440.USD","BK1610","LU2039709279.SGD","LU0819121731.USD","LU1242518857.USD","LU0359201612.USD","LU0348735423.USD","LU0320764599.SGD","02269","LU0588546209.SGD","LU0979878070.USD","LU0039217434.USD","LU0823426480.USD","SG9999002562.SGD","BK1521","LU0307460666.USD","LU0181495838.USD","LU0456827905.SGD","LU0516423091.SGD","LU0348825331.USD"],"gpt_icon":0},{"id":"2605473437","title":"Morgan Stanley’s Long Position in WuXi Biologics (Cayman)  Decreases to 2.11% on Jan 20 From 5.58% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2605473437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605473437?lang=en_us&edition=fundamental","pubTime":"2026-01-23 17:26","pubTimestamp":1769160400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nFWN3YO096:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2039709279.SGD","LU0572944931.SGD","LU0588546209.SGD","IE00B0JY6N72.USD","LU0348735423.USD","LU0823426308.USD","LU0140636845.USD","LU1242518857.USD","LU0307460666.USD","LU0979878070.USD","LU0516422440.USD","BK1521","BK1610","LU0039217434.USD","02269","LU0516422366.SGD","LU0052750758.USD","LU1880383366.USD","LU0417516738.SGD","SG9999002463.SGD","LU1242518931.SGD","LU0819121731.USD","BK1576","LU0516422952.EUR","LU0708995583.HKD","LU0456827905.SGD","BK1141","LU0359201612.USD","LU0051755006.USD","LU0181495838.USD","LU0326950275.SGD","LU0456846285.SGD","LU0823426480.USD","LU3063872942.SGD","LU0327786744.USD","SG9999002562.SGD","LU0348825331.USD","LU0516423091.SGD","LU1688375341.USD","BK1589","LU0417516902.SGD","LU1720050803.USD","LU0320764599.SGD","LU0043850808.USD","LU0856984785.SGD","LU0516423174.USD","LU0359202008.SGD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2605740387","title":"New UK MHRA Certifications and PatroLab Platform Might Change The Case For Investing In WuXi Biologics (Cayman) (SEHK:2269)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605740387","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605740387?lang=en_us&edition=fundamental","pubTime":"2026-01-23 16:39","pubTimestamp":1769157579,"startTime":"0","endTime":"0","summary":"WuXi Biologics recently announced that its Wuxi Drug Product Facility 5 and Drug Product Packaging Center received UK MHRA GMP certifications for commercial ophthalmic biologic manufacturing, alongside the launch of its PatroLabTM digital twin platform for real-time bioprocess monitoring and control.\nTogether, these developments highlight WuXi Biologics’ growing role as a globally compliant manufacturer that is integrating advanced digital technologies to enhance biologics quality and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/new-uk-mhra-certifications-and-patrolab-platform-might-chang","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/new-uk-mhra-certifications-and-patrolab-platform-might-chang","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0417516738.SGD","LU0823426308.USD","LU0572944931.SGD","02269","LU0516422952.EUR","LU0051755006.USD","91347","LU0052750758.USD","BK1610","LU0588546209.SGD","SG9999002463.SGD","LU0320764599.SGD","LU0359201612.USD","LU0819121731.USD","BK1521","LU0307460666.USD","LU0516423174.USD","LU0516422366.SGD","BK1576","IE00B0JY6N72.USD","LU0348825331.USD","LU0856984785.SGD","LU0456827905.SGD","LU0140636845.USD","LU1242518857.USD","LU1720050803.USD","LU1688375341.USD","LU0359202008.SGD","LU1794554557.SGD","LU0181495838.USD","LU3063872942.SGD","BK1589","LU0417516902.SGD","LU0979878070.USD","LU2039709279.SGD","LU0708995583.HKD","LU0326950275.SGD","LU1880383366.USD","LU0516422440.USD","LU0823426480.USD","LU0039217434.USD","LU0043850808.USD","LU0327786744.USD","LU1242518931.SGD","BK1141","LU0456846285.SGD","LU0348735423.USD","SG9999002562.SGD","LU0516423091.SGD"],"gpt_icon":0},{"id":"1191533477","title":"CLSA Maintains Outperform Rating on WUXI BIO (02269), Sees Enhanced Visibility for Growth Acceleration","url":"https://stock-news.laohu8.com/highlight/detail?id=1191533477","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191533477?lang=en_us&edition=fundamental","pubTime":"2026-01-23 11:42","pubTimestamp":1769139736,"startTime":"0","endTime":"0","summary":"Since January 20, WUXI BIO's (02269) stock performance has surpassed that of its mainland CRO peers and the overall healthcare sector. The firm attributes this relative resilience to several factors:...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0327786744.USD","LU0359202008.SGD","LU0516423174.USD","LU0708995583.HKD","LU1880383366.USD","LU0181495838.USD","LU0052750758.USD","LU0823426480.USD","BK1610","LU0516423091.SGD","02269","LU1688375341.USD","LU0819121731.USD","LU0823426308.USD","LU1794554557.SGD","LU0417516738.SGD","LU0359201612.USD","LU0326950275.SGD","LU0320764599.SGD","LU0572944931.SGD","SG9999002463.SGD","IE00B0JY6N72.USD","LU1242518857.USD","LU0348735423.USD","LU0516422952.EUR","LU0348825331.USD","LU0307460666.USD","LU0856984785.SGD","BK1141","LU0979878070.USD","LU1242518931.SGD","LU0456827905.SGD","BK1589","LU2039709279.SGD","BK1521","SG9999002562.SGD","BK1576","LU0456846285.SGD","LU0516422440.USD","LU0417516902.SGD","LU1720050803.USD","LU0516422366.SGD","LU3063872942.SGD","LU0043850808.USD","LU0588546209.SGD","LU0039217434.USD","LU0051755006.USD","LU0140636845.USD"],"gpt_icon":0},{"id":"2605466875","title":"Wuxi Biologics (Cayman) Stock Advances 1.5% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2605466875","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605466875?lang=en_us&edition=fundamental","pubTime":"2026-01-22 16:32","pubTimestamp":1769070720,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. advanced 1.5% to 38.96 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 26629.96.This was the stock's second consecutive day of gains.Wuxi Biologics  Inc. closed 8.5% short of its 52-week high of HK$42.60, which the company reached Oct. 3.Trading volume totaled 35.4 million shares, compared to the 50-day average of 35.8 million shares.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052750758.USD","LU0456846285.SGD","SG9999002463.SGD","LU0417516902.SGD","LU0051755006.USD","LU1688375341.USD","LU0417516738.SGD","IE00B0JY6N72.USD","LU2039709279.SGD","LU0348825331.USD","91347","LU0307460666.USD","LU1794554557.SGD","LU1880383366.USD","LU0181495838.USD","LU0516422440.USD","LU0708995583.HKD","LU0572944931.SGD","LU0326950275.SGD","LU1242518931.SGD","LU0140636845.USD","LU3063872942.SGD","BK1589","LU0359202008.SGD","LU0588546209.SGD","LU1242518857.USD","SG9999002562.SGD","LU1720050803.USD","BK1610","LU0516422952.EUR","LU0516423091.SGD","LU0456827905.SGD","LU0043850808.USD","02269","LU0823426308.USD","LU0327786744.USD","LU0348735423.USD","LU0819121731.USD","LU0856984785.SGD","BK1141","LU0823426480.USD","LU0516422366.SGD","LU0359201612.USD","LU0039217434.USD","LU0516423174.USD","BK1521","BK1576","LU0979878070.USD","LU0320764599.SGD"],"gpt_icon":0},{"id":"2605438508","title":"Assessing WuXi Biologics (SEHK:2269) Valuation After New GMP Certifications And PatroLab Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2605438508","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605438508?lang=en_us&edition=fundamental","pubTime":"2026-01-22 02:32","pubTimestamp":1769020348,"startTime":"0","endTime":"0","summary":"WuXi Biologics (Cayman) (SEHK:2269) recently reported two compliance and technology milestones: fresh UK MHRA GMP certifications for key Wuxi plants and the launch of its PatroLabTM digital twin bioprocess platform.\nSee our latest analysis for WuXi Biologics (Cayman).\nThe latest compliance wins and PatroLabTM launch come as the share price sits at HK$38.4, with a 30-day share price return of 15.87% and a 1-year total shareholder return of 117.69%, while longer term three and five year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/assessing-wuxi-biologics-sehk2269-valuation-after-new-gmp-ce","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2269/wuxi-biologics-cayman-shares/news/assessing-wuxi-biologics-sehk2269-valuation-after-new-gmp-ce","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0051755006.USD","IE00B0JY6N72.USD","BK1610","LU0856984785.SGD","91347","LU0140636845.USD","LU0359201612.USD","LU0516422952.EUR","LU1880383366.USD","LU0516422366.SGD","BK1589","LU1688375341.USD","DCF","LU0417516902.SGD","LU0043850808.USD","LU0819121731.USD","LU0039217434.USD","LU0823426480.USD","LU0708995583.HKD","LU0979878070.USD","BK1141","SG9999002562.SGD","LU0052750758.USD","LU1720050803.USD","LU0327786744.USD","LU0456827905.SGD","LU0516423174.USD","BK1576","LU0417516738.SGD","LU0588546209.SGD","LU0359202008.SGD","LU0456846285.SGD","LU0326950275.SGD","LU3063872942.SGD","LU0181495838.USD","BK1521","LU1794554557.SGD","SG9999002463.SGD","LU0348825331.USD","LU1242518931.SGD","02269","LU0307460666.USD","LU1242518857.USD","LU0348735423.USD","LU0572944931.SGD","LU0823426308.USD","LU0516422440.USD","LU0320764599.SGD","LU0516423091.SGD","LU2039709279.SGD"],"gpt_icon":0},{"id":"2604710198","title":"Wuxi Biologics (Cayman) Stock Falls 2.0% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2604710198","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604710198?lang=en_us&edition=fundamental","pubTime":"2026-01-20 16:32","pubTimestamp":1768897920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. shed 2.0% to 37.10 Hong Kong dollars on what proved to be an all-around poor trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.3% to 26487.51.This was the stock's third consecutive day of losses.Wuxi Biologics  Inc. closed 13% below its 52-week high of HK$42.60, which the company achieved Oct. 3.Trading volume totaled 28.3 million shares, compared to the 50-day average of 35.8 million shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","LU0588546209.SGD","LU0417516738.SGD","LU1794554557.SGD","LU0348735423.USD","BK1610","LU0456846285.SGD","LU0516423174.USD","LU1242518931.SGD","LU1688375341.USD","LU1880383366.USD","LU0327786744.USD","SG9999002463.SGD","SG9999002562.SGD","LU1242518857.USD","LU0348825331.USD","LU0140636845.USD","LU0181495838.USD","LU0039217434.USD","LU0043850808.USD","LU3063872942.SGD","BK1576","LU0320764599.SGD","02269","LU0456827905.SGD","LU0417516902.SGD","LU0516423091.SGD","LU0326950275.SGD","LU0359201612.USD","LU0979878070.USD","LU0516422366.SGD","LU0359202008.SGD","LU0051755006.USD","LU0819121731.USD","BK1521","LU0708995583.HKD","LU0307460666.USD","BK1589","LU2039709279.SGD","LU0516422952.EUR","LU0823426308.USD","LU0572944931.SGD","LU0856984785.SGD","LU0052750758.USD","IE00B0JY6N72.USD","LU0516422440.USD","LU0823426480.USD","BK1141"],"gpt_icon":0},{"id":"2604189162","title":"Wuxi Biologics (Cayman) Stock Sheds 4.8% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2604189162","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604189162?lang=en_us&edition=fundamental","pubTime":"2026-01-19 16:30","pubTimestamp":1768811400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. slid 4.8% to 37.86 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.0% to 26563.90.This was the stock's second consecutive day of losses.Wuxi Biologics  Inc. closed 11% short of its 52-week high of HK$42.60, which the company reached Oct. 3.Trading volume totaled 41.3 million shares, compared to the 50-day average of 35.4 million shares.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU3063872942.SGD","LU1242518857.USD","LU0327786744.USD","LU2039709279.SGD","LU0417516902.SGD","LU0320764599.SGD","LU0051755006.USD","LU0572944931.SGD","LU1242518931.SGD","LU0516423174.USD","LU0856984785.SGD","SG9999002562.SGD","LU0039217434.USD","BK1521","LU0456846285.SGD","LU0359202008.SGD","LU1880383366.USD","LU0181495838.USD","LU0307460666.USD","LU0417516738.SGD","LU0516422952.EUR","LU0819121731.USD","LU0516422440.USD","LU0979878070.USD","IE00B0JY6N72.USD","LU1720050803.USD","LU0516422366.SGD","SG9999002463.SGD","BK1141","BK1576","LU0588546209.SGD","LU0326950275.SGD","LU0052750758.USD","LU0516423091.SGD","LU0708995583.HKD","LU0823426308.USD","BK1589","LU0140636845.USD","LU0348735423.USD","LU1794554557.SGD","LU0456827905.SGD","LU0348825331.USD","LU0043850808.USD","LU0359201612.USD","02269","BK1610","LU0823426480.USD","LU1688375341.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.wuxibiologics.com","stockEarnings":[{"period":"1week","weight":-0.0454},{"period":"1month","weight":0.0907},{"period":"3month","weight":0.0446},{"period":"6month","weight":0.2452},{"period":"1year","weight":0.8577},{"period":"ytd","weight":0.1628}],"compareEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":0.019},{"period":"3month","weight":0.0136},{"period":"6month","weight":0.08},{"period":"1year","weight":0.2914},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.052868},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.004084},{"month":3,"riseRate":0.625,"avgChangeRate":0.020153},{"month":4,"riseRate":0.375,"avgChangeRate":-0.000625},{"month":5,"riseRate":0.5,"avgChangeRate":0.00166},{"month":6,"riseRate":0.625,"avgChangeRate":0.064583},{"month":7,"riseRate":0.666667,"avgChangeRate":0.081469},{"month":8,"riseRate":0.555556,"avgChangeRate":0.030253},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056337},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.033632},{"month":11,"riseRate":0.444444,"avgChangeRate":0.025584},{"month":12,"riseRate":0.555556,"avgChangeRate":0.009161}],"exchange":"SEHK","name":"WUXI BIO","nameEN":"WUXI BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"WUXI BIO(02269),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest WUXI BIO(02269) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"WUXI BIO,02269,WUXI BIO股票,WUXI BIO股票老虎,WUXI BIO股票老虎国际,WUXI BIO行情,WUXI BIO股票行情,WUXI BIO股价,WUXI BIO股市,WUXI BIO股票价格,WUXI BIO股票交易,WUXI BIO股票购买,WUXI BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"WUXI BIO(02269),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest WUXI BIO(02269) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}